SCHEMBL5073702

SCHEMBL5073702

C[C@H](CC(=O)O)c1ccc(CO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.57
ACHE P22303 1/20 0.44
ITGB1 P05556 2/20 0.44
ITGA4 P13612 2/20 0.44
PTGS1 P23219 4/20 0.42
PTGS2 P35354 4/20 0.42
LMNA P02545 2/20 0.42
CYP2C9 P11712 2/20 0.42
AKR1C3 P42330 2/20 0.42
CXCR1 P25024 2/20 0.42
CXCR2 P25025 2/20 0.42
ESR1 P03372 2/20 0.42
TSHR P16473 2/20 0.42
ALB P02768 1/20 0.42
ALOX5 P09917 1/20 0.42
RARB P10826 1/20 0.42
ADRB3 P13945 1/20 0.42
NFKB1 P19838 1/20 0.42
HTR2A P28223 1/20 0.42
NR1I3 Q14994 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070994 1.00 FFAR1 (0.57) FFAR1ACHEITGB1ITGA4PTGS1
SCHEMBL5070991 1.00 FFAR1 (0.57) FFAR1ACHEITGB1ITGA4PTGS1
SCHEMBL11333006 0.85 FFAR1 (0.57) FFAR1ACHEITGB1ITGA4PTGS1
SCHEMBL16527044 0.85 FFAR1 (0.57) FFAR1ACHEITGB1ITGA4PTGS1
SCHEMBL16527041 0.85 FFAR1 (0.57) FFAR1ACHEITGB1ITGA4PTGS1
SCHEMBL3972122 0.83 PTGS1 (0.62) FFAR1PTGS1PTGS2LMNACYP2C9
SCHEMBL5572746 0.83 PTGS1 (0.62) FFAR1PTGS1PTGS2LMNACYP2C9
SCHEMBL11432578 0.83 FFAR1 (0.56) FFAR1ACHEITGB1ITGA4ALDH1A1
SCHEMBL11332403 0.82 FFAR1 (0.62) FFAR1ACHELMNACYP2C9TSHR
SCHEMBL27594603 0.81 PTGS1 (0.43) FFAR1PTGS1PTGS2LMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410984-B2 Compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-12 US disclosed
US-20050288337-A1 Novel compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-29 US disclosed
EP-1539696-A2 PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES TANABE SEIYAKU CO., LTD. (JP) 2005-06-15 EP disclosed
WO-2004014859-A2 PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES TANABE SEIYAKU CO., LTD. (JP) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288337-A1 Novel compounds ITGB4, ITGA4, ITGB5 FFAR1 2500/4885ACHE 2329/4885ITGB1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.